These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31367864)

  • 1. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
    Saber S; Khodir AE; Soliman WE; Salama MM; Abdo WS; Elsaeed B; Nader K; Abdelnasser A; Megahed N; Basuony M; Shawky A; Mahmoud M; Medhat R; Eldin AS
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1591-1604. PubMed ID: 31367864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Saber S; Mahmoud AAA; Goda R; Helal NS; El-Ahwany E; Abdelghany RH
    Toxicol Lett; 2018 Oct; 295():32-40. PubMed ID: 29859236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
    Younis NS; Ghanim AMH; Saber S
    Sci Rep; 2019 Dec; 9(1):19095. PubMed ID: 31836811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-κB signalling in the context of PPARγ agonistic activity.
    Saber S; Basuony M; Eldin AS
    Arch Biochem Biophys; 2019 Aug; 671():185-195. PubMed ID: 31326516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactosylated Chitosan Nanoparticles Potentiate the Anticancer Effects of Telmisartan In Vitro and in a
    Nasr M; Kira AY; Saber S; Essa EA; El-Gizawy SA
    Mol Pharm; 2023 Sep; 20(9):4758-4769. PubMed ID: 37585079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
    Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
    Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
    Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
    Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
    Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.
    Yang L; Inokuchi S; Roh YS; Song J; Loomba R; Park EJ; Seki E
    Gastroenterology; 2013 May; 144(5):1042-1054.e4. PubMed ID: 23391818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts.
    Wang C; Jiang X; Huang B; Zhou W; Cui X; Zheng C; Liu F; Bi J; Zhang Y; Luo H; Yuan L; Yang J; Yu Y
    BMC Cancer; 2021 Nov; 21(1):1276. PubMed ID: 34823500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemopreventive and antitumor effects of benzyl isothiocynate on HCC models: A possible role of HGF /pAkt/ STAT3 axis and VEGF.
    Zakaria S; Helmy MW; Salahuddin A; Omran G
    Biomed Pharmacother; 2018 Dec; 108():65-75. PubMed ID: 30216802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Nasr M; Selima E; Hamed O; Kazem A
    Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor.
    Zhou L; Wang DS; Li QJ; Sun W; Zhang Y; Dou KF
    Oncol Rep; 2012 Sep; 28(3):874-82. PubMed ID: 22736202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
    Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
    Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
    Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
    Hong M; Almutairi MM; Li S; Li J
    Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.